JP6783230B2 - ヒストンデメチラーゼのインヒビターとしてのピロリドンアミド化合物 - Google Patents
ヒストンデメチラーゼのインヒビターとしてのピロリドンアミド化合物 Download PDFInfo
- Publication number
- JP6783230B2 JP6783230B2 JP2017518802A JP2017518802A JP6783230B2 JP 6783230 B2 JP6783230 B2 JP 6783230B2 JP 2017518802 A JP2017518802 A JP 2017518802A JP 2017518802 A JP2017518802 A JP 2017518802A JP 6783230 B2 JP6783230 B2 JP 6783230B2
- Authority
- JP
- Japan
- Prior art keywords
- membered
- carbocyclyl
- alkyl
- compound according
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 Cc1cc(Oc2ccccc2)cc(*=C)n1 Chemical compound Cc1cc(Oc2ccccc2)cc(*=C)n1 0.000 description 20
- UECKGIBZRAQRNT-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CC1N(C=CC=C1C)C1=O)=O Chemical compound CC(C)(C)OC(N(CC1)CC1N(C=CC=C1C)C1=O)=O UECKGIBZRAQRNT-UHFFFAOYSA-N 0.000 description 1
- APCBTRDHCDOPNY-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CC1O)=O Chemical compound CC(C)(C)OC(N(CC1)CC1O)=O APCBTRDHCDOPNY-UHFFFAOYSA-N 0.000 description 1
- DZUBTKLPIBEHSR-JTQLQIEISA-N CC(C)(C)OC(N(CC1)C[C@H]1NC(C1CC1)=O)=O Chemical compound CC(C)(C)OC(N(CC1)C[C@H]1NC(C1CC1)=O)=O DZUBTKLPIBEHSR-JTQLQIEISA-N 0.000 description 1
- HDIGBKXZIAJVFB-UHFFFAOYSA-N CC(C)C(C1)=NNC1C(N(CC1)CC1NC(NC)=O)=O Chemical compound CC(C)C(C1)=NNC1C(N(CC1)CC1NC(NC)=O)=O HDIGBKXZIAJVFB-UHFFFAOYSA-N 0.000 description 1
- BNBACRJYRCHOJC-UHFFFAOYSA-N CC(C)c1n[nH]c(C(N(CC2)CC2Nc2ncccc2)=O)c1 Chemical compound CC(C)c1n[nH]c(C(N(CC2)CC2Nc2ncccc2)=O)c1 BNBACRJYRCHOJC-UHFFFAOYSA-N 0.000 description 1
- DMNBHKDYAMCUIV-UHFFFAOYSA-N CC(C)c1n[nH]c(C(N(CC2)CC2c2cc(OC)cc(C)n2)=O)c1 Chemical compound CC(C)c1n[nH]c(C(N(CC2)CC2c2cc(OC)cc(C)n2)=O)c1 DMNBHKDYAMCUIV-UHFFFAOYSA-N 0.000 description 1
- HOHNWNOHHOMLDU-UHFFFAOYSA-N CC(C)c1nc(C)cc(-c2c[n](C)nc2)c1 Chemical compound CC(C)c1nc(C)cc(-c2c[n](C)nc2)c1 HOHNWNOHHOMLDU-UHFFFAOYSA-N 0.000 description 1
- HFBWRCZRDIVAMQ-UHFFFAOYSA-N CC(c1n[nH]c(C(O)=O)c1)=O Chemical compound CC(c1n[nH]c(C(O)=O)c1)=O HFBWRCZRDIVAMQ-UHFFFAOYSA-N 0.000 description 1
- LTBGAGHQQLYBFD-UHFFFAOYSA-N CCC(C1)N=C(C)C=C1NCc1ccccc1 Chemical compound CCC(C1)N=C(C)C=C1NCc1ccccc1 LTBGAGHQQLYBFD-UHFFFAOYSA-N 0.000 description 1
- BVNIREPGHLFKNZ-UHFFFAOYSA-N CNC(C1CC1)=O Chemical compound CNC(C1CC1)=O BVNIREPGHLFKNZ-UHFFFAOYSA-N 0.000 description 1
- SCWKRWCUMCMVPW-UHFFFAOYSA-N CNC(Oc1ccccc1)=O Chemical compound CNC(Oc1ccccc1)=O SCWKRWCUMCMVPW-UHFFFAOYSA-N 0.000 description 1
- CRSQCKSFDSBUPQ-UHFFFAOYSA-N Cc1cc(-c2c[n](C)nc2)cc(C)n1 Chemical compound Cc1cc(-c2c[n](C)nc2)cc(C)n1 CRSQCKSFDSBUPQ-UHFFFAOYSA-N 0.000 description 1
- NNOGVLOFSVCMBY-UHFFFAOYSA-N Cc1cc(-c2ccccn2)cc(C)n1 Chemical compound Cc1cc(-c2ccccn2)cc(C)n1 NNOGVLOFSVCMBY-UHFFFAOYSA-N 0.000 description 1
- CFIHITRYALVMCY-UHFFFAOYSA-N Cc1cc(C(N(C)C)=O)cc(C)n1 Chemical compound Cc1cc(C(N(C)C)=O)cc(C)n1 CFIHITRYALVMCY-UHFFFAOYSA-N 0.000 description 1
- MLDMYLXCMZTSHX-UHFFFAOYSA-N Cc1cc(C(OC)=O)cc(C)n1 Chemical compound Cc1cc(C(OC)=O)cc(C)n1 MLDMYLXCMZTSHX-UHFFFAOYSA-N 0.000 description 1
- TXRZXFOOTYXLOQ-QGRYRQEDSA-N N/C(/C(N(CC1)CC1NC(C1CC1)=O)=O)=C\C(Cc1ccccc1)=N Chemical compound N/C(/C(N(CC1)CC1NC(C1CC1)=O)=O)=C\C(Cc1ccccc1)=N TXRZXFOOTYXLOQ-QGRYRQEDSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2014/088309 | 2014-10-10 | ||
| CN2014088309 | 2014-10-10 | ||
| PCT/US2015/054949 WO2016057924A1 (en) | 2014-10-10 | 2015-10-09 | Pyrrolidine amide compounds as histone demethylase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017530984A JP2017530984A (ja) | 2017-10-19 |
| JP2017530984A5 JP2017530984A5 (en:Method) | 2018-11-22 |
| JP6783230B2 true JP6783230B2 (ja) | 2020-11-11 |
Family
ID=54337935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017518802A Expired - Fee Related JP6783230B2 (ja) | 2014-10-10 | 2015-10-09 | ヒストンデメチラーゼのインヒビターとしてのピロリドンアミド化合物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10022354B2 (en:Method) |
| EP (1) | EP3204379B1 (en:Method) |
| JP (1) | JP6783230B2 (en:Method) |
| CN (1) | CN107912040B (en:Method) |
| WO (1) | WO2016057924A1 (en:Method) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR102017010009A2 (pt) | 2016-05-27 | 2017-12-12 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
| MA45088A (fr) | 2016-05-27 | 2019-04-10 | Gilead Sciences Inc | Méthodes pour traiter des infections par le virus de l'hépatite b au moyen d'inhibiteurs de ns5a, ns5b ou ns3 |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| ES2826748T3 (es) | 2016-09-02 | 2021-05-19 | Gilead Sciences Inc | Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll |
| ES2906581T3 (es) | 2016-09-02 | 2022-04-19 | Gilead Sciences Inc | Compuestos moduladores de los receptores tipo Toll |
| SG11201903042VA (en) | 2016-10-14 | 2019-05-30 | Precision Biosciences Inc | Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome |
| TW201822637A (zh) | 2016-11-07 | 2018-07-01 | 德商拜耳廠股份有限公司 | 用於控制動物害蟲的經取代磺醯胺類 |
| EP3571200B8 (en) | 2017-01-17 | 2022-08-03 | HepaRegeniX GmbH | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| TWI820984B (zh) | 2017-01-31 | 2023-11-01 | 美商基利科學股份有限公司 | 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型 |
| JOP20180008A1 (ar) | 2017-02-02 | 2019-01-30 | Gilead Sciences Inc | مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| KR20190063745A (ko) * | 2017-11-30 | 2019-06-10 | (주)인핸스드바이오 | p34 단백질 및 NEDD4-1 단백질의 결합 억제제로서의 신규 화합물 및 이의 용도 |
| WO2019123340A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| US11203610B2 (en) | 2017-12-20 | 2021-12-21 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| MX2020008404A (es) | 2018-02-13 | 2020-09-25 | Gilead Sciences Inc | Inhibidores de molecula de muerte programada 1 (pd-1)/ligando de molecula de muerte programada 1 (pd-l1). |
| CN111788204B (zh) | 2018-02-26 | 2023-05-05 | 吉利德科学公司 | 作为hbv复制抑制剂的取代吡咯嗪化合物 |
| WO2019195181A1 (en) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| ES3035911T3 (en) | 2018-04-19 | 2025-09-11 | Gilead Sciences Inc | Pd-1/pd-l1 inhibitors |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| SI3820572T1 (sl) | 2018-07-13 | 2023-12-29 | Gilead Sciences, Inc. | Inhibitorji pd-1/pd-l1 |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| JP7017704B2 (ja) * | 2018-09-10 | 2022-02-09 | 株式会社島津製作所 | 生体膜ホスホイノシタイドの分離方法 |
| JP7158577B2 (ja) | 2018-10-24 | 2022-10-21 | ギリアード サイエンシーズ， インコーポレイテッド | Ｐｄ－１／ｐｄ－ｌ１阻害剤 |
| CN117105933A (zh) | 2018-10-31 | 2023-11-24 | 吉利德科学公司 | 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物 |
| LT3873903T (lt) | 2018-10-31 | 2024-05-10 | Gilead Sciences, Inc. | Pakeistieji 6-azabenzimidazolo junginiai, kaip hpk1 inhibitoriai |
| CN109852662B (zh) * | 2018-12-25 | 2021-02-19 | 华南农业大学 | 组蛋白甲基化H3K4me3在猪卵巢颗粒细胞中的应用 |
| WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| CA3129022C (en) | 2019-03-07 | 2023-08-01 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
| EP3935066A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
| JP7295283B2 (ja) | 2019-06-25 | 2023-06-20 | ギリアード サイエンシーズ， インコーポレイテッド | Ｆｌｔ３ｌ－ｆｃ融合タンパク質及び使用方法 |
| US20220289751A1 (en) * | 2019-07-17 | 2022-09-15 | Ono Pharmaceutical Co., Ltd. | Compound having kdm5 inhibitory activity and pharmaceutical use thereof |
| WO2021011891A1 (en) | 2019-07-18 | 2021-01-21 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| CR20220129A (es) | 2019-09-30 | 2022-05-06 | Gilead Sciences Inc | Vacunas para vhb y métodos de tratamiento de vhb |
| TW202130643A (zh) * | 2019-10-29 | 2021-08-16 | 美商百健Ｍａ公司 | 螺環o-醣蛋白-2-乙醯胺基-2-去氧-3-d-葡萄哌喃糖苷酶抑制劑 |
| EP4069729B1 (en) | 2019-12-06 | 2025-01-22 | Precision BioSciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| CN118702672A (zh) | 2020-01-29 | 2024-09-27 | 卡玛瑞制药有限公司 | 用于治疗皮肤病症的化合物和组合物 |
| CN111138289B (zh) * | 2020-02-27 | 2022-08-30 | 奥锐特药业(天津)有限公司 | 一种化合物及使用该化合物合成5-乙酰基-1h-吡唑-3-羧酸的工艺 |
| TW202421168A (zh) | 2020-03-20 | 2024-06-01 | 美商基利科學股份有限公司 | 4’-c-經取代-2-鹵基-2’-去氧腺苷核苷之前藥及其製造與使用方法 |
| CN115461338B (zh) * | 2020-05-07 | 2024-02-20 | 小野药品工业株式会社 | 具有kdm5抑制活性的3-氮杂二环(3.1.0)己烷衍生物及其用途 |
| CN116194144A (zh) | 2020-08-07 | 2023-05-30 | 吉利德科学公司 | 膦酰胺核苷酸类似物的前药及其药物用途 |
| WO2022087422A1 (en) * | 2020-10-22 | 2022-04-28 | Chulalongkorn University | Pyrrolidine-3-carboxamide derivatives and related uses |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| AU2022274607A1 (en) | 2021-05-13 | 2023-11-16 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| AU2022299051B2 (en) | 2021-06-23 | 2025-03-13 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| US11932634B2 (en) | 2021-06-23 | 2024-03-19 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| US11999733B2 (en) | 2021-06-23 | 2024-06-04 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| US11926628B2 (en) | 2021-06-23 | 2024-03-12 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7743829B2 (ja) * | 2021-11-05 | 2025-09-25 | 小野薬品工業株式会社 | Ｋｄｍ５阻害作用を有する化合物を含有する医薬組成物 |
| CN120187416A (zh) | 2022-11-11 | 2025-06-20 | 阿斯利康(瑞典)有限公司 | 用于治疗癌症的组合疗法 |
| CN116284202B (zh) * | 2023-03-28 | 2024-07-02 | 华侨大学 | 白桦脂酸的PROTACs化合物及其制备方法和应用 |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| US20250345390A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| WO2025240243A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| CA2066428C (en) | 1989-09-08 | 2000-11-28 | Bert Vogelstein | Structural alterations of the egf receptor gene in human gliomas |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| ES2166368T3 (es) | 1993-12-24 | 2002-04-16 | Merck Patent Gmbh | Inmunoconjugados. |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| US5679683A (en) | 1994-01-25 | 1997-10-21 | Warner-Lambert Company | Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| EP0772609B1 (en) | 1994-07-21 | 1999-02-24 | Akzo Nobel N.V. | Cyclic ketone peroxide formulations |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| EP0817775B1 (en) | 1995-03-30 | 2001-09-12 | Pfizer Inc. | Quinazoline derivatives |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| CA2222231A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
| NZ312665A (en) | 1995-07-06 | 1999-08-30 | Novartis Ag | Rrolopyrimidines(7h-pyrrolo[2,3-d]pyrimidine and preparation of these |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| CN1145614C (zh) | 1996-04-12 | 2004-04-14 | 沃尼尔·朗伯公司 | 酪氨酸激酶的不可逆抑制剂，其制药用途及药物组合物 |
| ES2186908T3 (es) | 1996-07-13 | 2003-05-16 | Glaxo Group Ltd | Compuestos heterociciclos condensados como inhibidores de pproteina-tirosina-quinasas. |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| PT980244E (pt) | 1997-05-06 | 2003-10-31 | Wyeth Corp | Utilizacao de compostos de quinazolina para o tratamento da doenca policistica renal |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| KR20010031813A (ko) | 1997-11-06 | 2001-04-16 | 윌리암 에이취 캘넌, 에곤 이 버그 | 결장 폴립 치료용 티로신 키나제 억제제로서의 퀴나졸린유도체의 용도 |
| NZ512189A (en) | 1998-11-19 | 2003-10-31 | Warner Lambert Co | N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4- yl-propoxy)-quinazolin-6-yl]-acrylamide useful as an irreversible inhibitor of tyrosine kinases |
| AU2009298981B2 (en) * | 2008-10-02 | 2012-09-27 | Asahi Kasei Pharma Corporation | 8-substituted isoquinoline derivative and use thereof |
| WO2012166387A1 (en) * | 2011-05-31 | 2012-12-06 | Theravance, Inc. | Neprilysin inhibitors |
| CA2871695A1 (en) * | 2012-05-22 | 2013-11-28 | F. Hoffmann-La Roche Ag | Substituted dipyridylamines and uses thereof |
| JP6297582B2 (ja) * | 2012-11-16 | 2018-03-20 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | ヒトホスファチジルイノシトール３−キナーゼデルタのプリン阻害剤 |
| AU2014249050B2 (en) * | 2013-03-12 | 2017-10-05 | Celgene Quanticel Research, Inc. | Histone dementhylase inhibitors |
| CN105980386B (zh) * | 2013-03-13 | 2021-08-13 | 基因泰克公司 | 吡唑并化合物及其用途 |
-
2015
- 2015-10-09 WO PCT/US2015/054949 patent/WO2016057924A1/en not_active Ceased
- 2015-10-09 JP JP2017518802A patent/JP6783230B2/ja not_active Expired - Fee Related
- 2015-10-09 CN CN201580066844.9A patent/CN107912040B/zh not_active Expired - Fee Related
- 2015-10-09 EP EP15784257.6A patent/EP3204379B1/en active Active
-
2017
- 2017-04-07 US US15/482,584 patent/US10022354B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN107912040A (zh) | 2018-04-13 |
| HK1253559A1 (zh) | 2019-06-21 |
| US10022354B2 (en) | 2018-07-17 |
| US20170312252A1 (en) | 2017-11-02 |
| WO2016057924A1 (en) | 2016-04-14 |
| EP3204379B1 (en) | 2019-03-06 |
| EP3204379A1 (en) | 2017-08-16 |
| CN107912040B (zh) | 2021-04-06 |
| JP2017530984A (ja) | 2017-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6783230B2 (ja) | ヒストンデメチラーゼのインヒビターとしてのピロリドンアミド化合物 | |
| US11084798B1 (en) | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | |
| JP7014765B2 (ja) | ピラゾロ化合物及びその使用 | |
| JP7014736B2 (ja) | がんの処置のためのピラゾロピリジン誘導体 | |
| JP6847844B2 (ja) | 治療用ピリダジン化合物およびその使用 | |
| JP6771464B2 (ja) | Ｃｂｐおよび／またはｅｐ３００インヒビターとしての、４，５，６，７−テトラヒドロ−１ｈ−ピラゾロ［４，３−ｃ］ピリジン−３−アミン化合物 | |
| EP2742040B1 (en) | Indazole compounds, compositions and methods of use | |
| KR20140071361A (ko) | 피라졸로[3,4-c]피리딘 화합물 및 사용 방법 | |
| JP2016529312A (ja) | 抗増殖性化合物 | |
| EP4436957A1 (en) | Therapeutic indazole compounds and methods of use in the treatment of cancer | |
| JP6889661B2 (ja) | ４，５−ジヒドロイミダゾール誘導体およびヒストンジメチラーゼ（ｋｄｍ２ｂ）インヒビターとしてのその使用 | |
| US10280149B2 (en) | Therapeutic compounds and uses thereof | |
| HK1253559B (zh) | 作為組蛋白脫甲基酶抑制劑的吡咯烷酰胺化合物 | |
| HK40005958B (zh) | 用於治疗癌症的吡唑并吡啶衍生物 | |
| HK1248695B (zh) | 用作cbp和/或ep300抑制劑的4，5，6，7-四氫-1h-吡唑並[4，3-c]吡啶-3-胺化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181005 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181005 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190614 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190613 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190912 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191216 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200522 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200821 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200925 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201021 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6783230 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |